1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Viemed Healthcare, Inc.
  6. News
  7. Summary
    VMD   CA92663R1055


Delayed Toronto Stock Exchange  -  04:00 2022-08-09 pm EDT
8.030 CAD   -4.97%
08/05VIEMED HEALTHCARE, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
08/04VIEMED HEALTHCARE : Download Investor Relations Presentation
08/03TRANSCRIPT : Viemed Healthcare, Inc., Q2 2022 Earnings Call, Aug 03, 2022
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Viemed Healthcare : Download Investor Relations Presentation

08/04/2022 | 03:58pm EDT



Investor Presentation

August 2022

Leading the Healthcare Industry in Home Respiratory Care

Slide 1


Disclaimers and Other Important Information

This presentation (the "Presentation") about Viemed Healthcare, Inc. ("Viemed") is dated as of August 2022. It is information in a summary form and does not purport to be complete. The data contained herein is derived from various internal and external sources. This Presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. No representation or warranty, express or implied, is made or given by or on behalf of Viemed or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. Viemed does not undertake or agree to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. No person has been authorized to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorized. The contents of this Presentation are not to be construed as legal, financial or tax advice.

Forward Looking Statements

Certain statements contained in this Presentation may constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "potential", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", or "projects", or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results "will", "should", "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including projected US DME expenditures and Viemed's technology and marketing initiatives and goals for the next 24 months, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect Viemed's current views and intentions with respect to future events, and current information available to Viemed, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which Viemed operates; Viemed may be subject to significant capital requirements and operating risks; the ability of Viemed to implement business strategies and pursue business opportunities; volatility in the market price of Viemed common shares; Viemed's novel business model; the risk that the impact of the COVID-19 pandemic and the actions taken by governmental authorities, individuals and companies in response to the pandemic on Viemed's business, financial condition and results of operations, including on Viemed's patient base, revenues, employees, and equipment and supplies; the clinical application of treatments that demonstrate positive results in a study may not be positively replicated or that such test results may not be predictive of actual treatment results or may not result in the adoption of such treatments by providers; the state of the capital markets; the availability of funds and resources to pursue operations; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers and the recall of certain Royal Philips BiPAP and CPAP and mechanical ventilator devices that Viemed distributes and sells; granting of permits and licenses in a highly regulated business; competition; low profit market segments; disruptions in or attacks (including cyber- attacks) on Viemed's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which Viemed is exposed; the failure of third parties to comply with their obligations; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by Viemed; Viemed's status as an emerging growth company; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, such as the COVID-19 pandemic, and claims resulting from such events or concerns; as well as those risk factors discussed or referred to in Viemed's disclosure documents filed with the U.S. Securities and Exchange Commission (the "SEC") available on the SEC's website at www.sec.gov, including Viemed's most recent Annual Report on Form 10-K and quarterly report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedar.com. Should any factor affect Viemed in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, Viemed does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this Presentation are made as of the date of this Presentation and Viemed undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

Market and Industry Data

Industry and market data used in this Presentation is unaudited and have been obtained from third-party industry publications and sources as well as from research reports prepared for other purposes. Viemed has not independently verified the data obtained from these sources and cannot assure you of the data's accuracy or completeness. This data is subject to change and cannot always be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties inherent in any statistical survey of market or industry data. You are cautioned not to give undue weight to such industry and market data.

Non-GAAP and Other Financial Information

This Presentation includes references to financial measures that are calculated and presented on the basis of methodologies other than in accordance with generally accepted accounting principles in the United States of America ("GAAP"), including the measures Net Revenue and Adjusted EBITDA. A reconciliation of certain of these non-GAAP financial measures to the nearest GAAP measure can be found in the Appendix to this Presentation.

No Offer or Solicitation

This Presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of Viemed in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Recipients of this Presentation who are considering acquiring securities of Viemed are referred to the entire body of publicly disclosed information regarding Viemed. The information is subject to material updating, revision and further amendment, and is qualified entirely by reference to Viemed's publicly disclosed information.

Slide 2

Viemed at a Glance

  • Largest independent specialized provider of non-invasive ventilation (NIV) in the US home respiratory health care industry
  • Highly profitable with a 40% CAGR in revenue growth since 2010
  • Service offering includes 24x7 in home respiratory care including specialized respiratory therapists and medical devices
  • Headquartered in Lafayette, Louisiana
  • Currently serving over 41,500 patients
  • Listed on NASDAQ (VMD) as well as listed on TSX (VMD.TO)

Viemed Healthcare, Inc. | Investor Presentation

Slide 3

Our Journey









Slide 4


Annual Revenues: $0.24M USD

Respiratory DME specializing in CPAPS & Oxygen


Annual Revenues: $3.58M USD

Home Sleep Delivered - Specializing in home sleep tests


Annual Revenues: $4.60M USD

Non Invasive ventilator introduced to market


Annual Revenues: $35.5M USD

Acquired by publiccompany


Annual Revenues: $41.3M USD


Annual Revenues: $58.4M USD


Annual Revenues: $80.3M USD


Annual Revenues: $117.1M USD

Key Investment Consideration

Specialized US based respiratory healthcare services company

  • Focused on Chronic Obstructive Pulmonary Disease (COPD) and growing aging population
  • $50 billion of annual healthcare cost in the U.S. spent on COPD

Significant Market Growth Opportunity

  • 10,000 baby boomers are turning 65 every day (26% of the US population)
  • Expansion of service to underserved VA patients

Favorable Market Trend

  • Increasing need supported by Government for effective homecare solutions to reduce patient hospital re-admissions
    • increase system efficiency
    • offer better comfort and family lifestyle options
    • save money for patients, insurers, government

Viemed Healthcare, Inc. | Investor Presentation

Slide 5

This is an excerpt of the original content. To continue reading it, access the original document here.


Viemed Healthcare Inc. published this content on 04 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2022 19:57:03 UTC.

© Publicnow 2022
08/05VIEMED HEALTHCARE, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (for..
08/04VIEMED HEALTHCARE : Download Investor Relations Presentation
08/03TRANSCRIPT : Viemed Healthcare, Inc., Q2 2022 Earnings Call, Aug 03, 2022
08/02Viemed Healthcare, Inc. Announces Earnings Guidance for the Third Quarter of 2022
08/02Earnings Flash (VMD.TO) VIEMED HEALTHCARE Expects to generate net revenues of Near US$3..
08/02Earnings Flash (VMD.TO) VIEMED HEALTHCARE Posts Q2 Net revenues attributable to the Com..
08/02Viemed Healthcare Announces Second Quarter 2022 Financial Results
08/02MANAGEMENT'S DISCUSSION AND ANALYSIS (Tabular amounts expressed in thousands of U..
08/02Viemed Healthcare, Inc. Reports Earnings Results for the Second Quarter and Six Months ..
More news
Analyst Recommendations on VIEMED HEALTHCARE, INC.
More recommendations
Financials (USD)
Sales 2022 138 M - -
Net income 2022 5,70 M - -
Net Debt 2022 - - -
P/E ratio 2022 26,3x
Yield 2022 -
Capitalization 238 M 238 M -
Capi. / Sales 2022 1,73x
Capi. / Sales 2023 1,49x
Nbr of Employees 715
Free-Float 88,4%
Duration : Period :
Viemed Healthcare, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIEMED HEALTHCARE, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 4
Last Close Price 6,23 $
Average target price 11,37 $
Spread / Average Target 82,4%
EPS Revisions
Managers and Directors
Casey Hoyt Chief Executive Officer & Director
Michael Moore President
Trae Fitzgerald Chief Financial Officer
Randolph E. Dobbs Chairman
William Frazier Chief Medical Officer & Director
Sector and Competitors
1st jan.Capi. (M$)
HCA HEALTHCARE, INC.-17.17%60 660
REDE D'OR SÃO LUIZ S.A.-19.76%13 864